Clinical Application of Biological Markers for Treatments of Resectable Non-small-cell Lung Cancers

Overview

Journal Br J Cancer

Specialty Oncology

Date 2005 Mar 24

PMID 15785747

Citations 26

Authors

C Huang

D Liu

D Masuya

T Nakashima

K Kameyama

S Ishikawa

M Ueno

R Haba

H Yokomise

Affiliations

Soon will be listed here.

Abstract

We performed a clinical study to identify biological markers useful for the treatment of resectable non-small-cell lung cancers (NSCLCs). In all, 173 patients were studied. By immunohistochemistry, we evaluated the Ki-67 proliferation index, tumour vascularity, thymidylate synthase (TS), vascular endothelial growth factor (VEGF)-A, VEGF-C, and E (epithelial)-cadherin. Concerning the survival of NSCLC patients, tumour vascularity (P<0.01), VEGF-A status (P=0.03), VEGF-C status (P=0.03), and E-cadherin status (P=0.03) were significant prognostic factors in patients with stage I NSCLCs. The Ki-67 proliferation index (P=0.02) and TS status (P<0.01) were significant prognostic factors in patients with stage II-III NSCLCs. In patients with stage II-III NSCLCs, furthermore, the survival of UFT (a combination of tegafur and uracil)-treated patients with TS-negative tumours was significantly better than those of any other patients. Biological markers associated with tumour angiogenesis or metastasis are useful for the detection of aggressive tumours among early-stage NSCLCs. Postoperative chemotherapy might be necessary in such tumours even in stage I. In contrast, tumour proliferation rate and TS status are useful markers for identifying less aggressive tumours in locally advanced NSCLCs. Thymidylate synthase expression is also a useful marker to evaluate responsiveness of UFT-based chemotherapy for these tumours.

Citing Articles

Terahertz Sensing of L-Valine and L-Phenylalanine Solutions.

Shu J, Zhou X, Hao J, Zhao H, An M, Zhang Y Sensors (Basel). 2024; 24(12).

PMID: 38931580 PMC: 11207273. DOI: 10.3390/s24123798.

Chemotherapy for Lung Cancer in the Era of Personalized Medicine.

Lee S Tuberc Respir Dis (Seoul). 2019; 82(3):179-189.

PMID: 30841023 PMC: 6609523. DOI: 10.4046/trd.2018.0068.

Overexpression of KIF20A confers malignant phenotype of lung adenocarcinoma by promoting cell proliferation and inhibiting apoptosis.

Zhao X, Zhou L, Li X, Ni J, Chen P, Ma R Cancer Med. 2018; 7(9):4678-4689.

PMID: 30105795 PMC: 6143951. DOI: 10.1002/cam4.1710.

Augmented expression of Ki-67 is correlated with clinicopathological characteristics and prognosis for lung cancer patients: an up-dated systematic review and meta-analysis with 108 studies and 14,732 patients.

Wei D, Chen W, Meng R, Zhao N, Zhang X, Liao D Respir Res. 2018; 19(1):150.

PMID: 30103737 PMC: 6088431. DOI: 10.1186/s12931-018-0843-7.

Evaluation of Detection Methods and Values of Circulating Vascular Endothelial Growth Factor in Lung Cancer.

Guo S, Martin M, Tian C, Cui J, Wang L, Wu S J Cancer. 2018; 9(7):1287-1300.

PMID: 29675110 PMC: 5907677. DOI: 10.7150/jca.22020.

References

Wada H, Hitomi S, TERAMATSU T . Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. West Japan Study Group for Lung Cancer Surgery. J Clin Oncol. 1996; 14(4):1048-54. DOI: 10.1200/JCO.1996.14.4.1048. View

Navalgund L, Rossana C, Muench A, Johnson L . Cell cycle regulation of thymidylate synthetase gene expression in cultured mouse fibroblasts. J Biol Chem. 1980; 255(15):7386-90. View

Machtay M, Lee J, Stevenson J, Shrager J, Algazy K, Treat J . Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response. J Thorac Cardiovasc Surg. 2004; 127(1):108-13. DOI: 10.1016/j.jtcvs.2003.07.027. View

Angus S, Wheeler L, Ranmal S, Zhang X, Markey M, Mathews C . Retinoblastoma tumor suppressor targets dNTP metabolism to regulate DNA replication. J Biol Chem. 2002; 277(46):44376-84. DOI: 10.1074/jbc.M205911200. View

Horie N, Aiba H, Oguro K, Hojo H, Takeishi K . Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5'-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct. 1995; 20(3):191-7. DOI: 10.1247/csf.20.191. View

Mbalaviele G, Dunstan C, Sasaki A, Williams P, Mundy G, Yoneda T . E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model. Cancer Res. 1996; 56(17):4063-70. View

Johnston P, Lenz H, Leichman C, Danenberg K, Allegra C, Danenberg P . Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res. 1995; 55(7):1407-12. View

Folkman J . Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995; 1(1):27-31. DOI: 10.1038/nm0195-27. View

Kajita T, Ohta Y, Kimura K, Tamura M, Tanaka Y, Tsunezuka Y . The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer. Br J Cancer. 2001; 85(2):255-60. PMC: 2364042. DOI: 10.1054/bjoc.2001.1882. View

10.

Matsuyama K, Chiba Y, Sasaki M, Tanaka H, Muraoka R, Tanigawa N . Tumor angiogenesis as a prognostic marker in operable non-small cell lung cancer. Ann Thorac Surg. 1998; 65(5):1405-9. DOI: 10.1016/s0003-4975(97)01416-1. View

11.

Chu E, Copur S, Ju J, Chen T, Khleif S, Voeller D . Thymidylate synthase protein and p53 mRNA form an in vivo ribonucleoprotein complex. Mol Cell Biol. 1999; 19(2):1582-94. PMC: 116086. DOI: 10.1128/MCB.19.2.1582. View

12.

Omura K, Uno Y, Kawakami K, Kanehira E, Tawaraya K, Tsukayama M . Expression of thymidylate synthase in human gastric and colorectal adenocarcinomas is upregulated by p16/INK4. Hepatogastroenterology. 2000; 47(33):742-5. View

13.

Nakashima T, Huang C, Liu D, Kameyama K, Masuya D, Ueno M . Expression of vascular endothelial growth factor-A and vascular endothelial growth factor-C as prognostic factors for non-small cell lung cancer. Med Sci Monit. 2004; 10(6):BR157-65. View

14.

Arinaga M, Noguchi T, Takeno S, Chujo M, Miura T, Uchida Y . Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma. Cancer. 2003; 97(2):457-64. DOI: 10.1002/cncr.11073. View

15.

Dingemans A, Witlox M, Stallaert R, van der Valk P, Postmus P, Giaccone G . Expression of DNA topoisomerase IIalpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancer. Clin Cancer Res. 1999; 5(8):2048-58. View

16.

Adachi M, Taki T, Konishi T, Huang C, Higashiyama M, Miyake M . Novel staging protocol for non-small-cell lung cancers according to MRP-1/CD9 and KAI1/CD82 gene expression. J Clin Oncol. 1998; 16(4):1397-406. DOI: 10.1200/JCO.1998.16.4.1397. View

17.

Skobe M, Hawighorst T, Jackson D, Prevo R, Janes L, Velasco P . Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med. 2001; 7(2):192-8. DOI: 10.1038/84643. View

18.

Scagliotti G, Micela M, Gubetta L, Leonardo E, Cappia S, Borasio P . Prognostic significance of Ki67 labelling in resected non small cell lung cancer. Eur J Cancer. 1993; 29A(3):363-5. DOI: 10.1016/0959-8049(93)90387-u. View

19.

Mendelsohn J, Baselga J . Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol. 2003; 21(14):2787-99. DOI: 10.1200/JCO.2003.01.504. View

20.

Beck A, Etienne M, Cheradame S, Fischel J, Formento P, Renee N . A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer. 1994; 30A(10):1517-22. DOI: 10.1016/0959-8049(94)00216-r. View